ClinicalTrials.gg
RecruitingNCT06441669Updated Jun 4, 2024

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

An observational study in Cytomegalovirus Infection Reactivation, sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Anhui Provincial Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cytomegalovirus Infections with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Cytomegalovirus Infections · China.

Planned enrollment
8th of 12
60 · median 111
Started
2024
with 2 others
Observational
12 of 23
4 open now
Registered
16th of 23
by date
Lead sponsor
1 of 23
Anhui Provincial Hospital

Among the 23 studies in Cytomegalovirus Infections with a site in China, this one is the 8th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2024, is one of 12 observational ones, and was the 16th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

8 of the 23 studies in Cytomegalovirus Infections with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cytomegalovirus Infections with a site in China, or all of them as a file.
02

Study summary

To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation

Read the detailed description

To explore the effect of letermovir prophylaxis on cytomegalovirus-specific and other lymphocyte subsets immune reconstitution post unrelated cord blood transplantation, and to analyze the potential mechanism and risk factors of late CMV reactivation after letermovir discontinuation.

03

Conditions studied

  • Cytomegalovirus Infection Reactivation

Keywords

  • Cytomegalovirus Infection
  • Umbilical Cord Blood Transplantation
  • CMV-Specific Immune Reconstitution
  • Letermovir
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study consists 60 cases recipients of UCBT. All patients will receive letermovir prophylaxis within 0-28 days post UCBT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are receiving a first unrelated cord blood transplantation (UCBT).
  • Patients start letemovir prophylaxis within 0-28 days post UCBT.

Exclusion criteria

Exclusion Criteria:

  • Patients having active CMV DNAemia at the time of letermovir initiation.
  • Patients recruited in a clinical study on an anti-CMV trial.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • letermovir group

    Patients will be given Letermovir with a recommended dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine or according to clinical instructions) from +1 day to +100 days after UCBT.

    Drug: Letermovir

Interventions

  • Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.

06

What researchers measure

Primary outcomes

  1. Numbers of immune cells in peripheral blood

    PBMCs from UCBT recipients were collected at 1 month, 2 month, 3 month, and 6 month and 12 month after HSCT, and tested for CMV-specific T cells, NK cells, T cells and other subsets.

    Time frame: one year

  2. CMV DNAemia

    CMV DNAemia is defined as the detection of CMV DNA in samples of plasma, whole blood or isolated peripheral blood leukocyte.

    Time frame: one year

  3. Incidence of refractory CMV infection

    Refractory CMV infection is defined as CMV viral load remaining at the same level or increasing despite appropriately doses of antiviral therapy for at least 2 weeks

    Time frame: one year

  4. late CMV reactivation

    Late CMV reactivation is defined as reactivation that occurs 100 days post UCBT, which means reactivation after discontinuing LET prophylaxis.

    Time frame: one year

Secondary outcomes

  1. Treatment-ralated mortality

    Treatment-ralated mortality

    Time frame: one year

  2. Incidence of other viral infection and viral-associated disease

    Other viral infection and viral-associated diseases including EBV, ADV, HHV-6, BKV and HSV

    Time frame: one year

  3. Overall survival

    Overall survival

    Time frame: one year

  4. serum immunoglobulin assay

    The serum levels of IgG, IgM, and IgA were measured

    Time frame: 1,3,6,9 month post UCBT

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2026, 24 months after the start.

Of 30 observational studies under Cytomegalovirus Infections, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 61. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
May 1, 2024
Primary completionEst.
May 1, 2026
CompletionEst.
May 20, 2026
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06441669
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
May 1, 2024
Primary completion
May 1, 2026 (estimated)
Completion
May 20, 2026 (estimated)
Last update
Jun 4, 2024

Study contacts

Xiaoyu Zhu, ph.D
Contact
xiaoyuz@ustc.edu.cn
15255456091
Bingbing Yan
Contact
bing0415@mail.ustc.edu.cn
15993691727
Xiaoyu Zhu, ph.D
principal investigator · The First Affiliated Hospital of University of Science and Technology of China (Anhui Provicial Hospital)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion